The Resolute DES platform, including Resolute Onyx and Resolute Integrity DES, has received expanded indication to treat coronary artery disease who have de novo CTO, which is a
The post FDA grants expanded approval for Medtronic’s Resolute drug-eluting stent platform appeared first on Compelo Medical Devices.